(Q34661348)

3 August 2017

1 reference

title

The safety of antidepressant drugs during pregnancy (English)

1 reference

3 August 2017

Bengt Källén

1

1 reference

PubMed ID

17688379

3 August 2017

language of work or name

English

0 references

publication date

1 July 2007

1 reference

Expert Opinion on Drug Safety

3 August 2017

1 reference

3 August 2017

6

1 reference

3 August 2017

357-370

1 reference

3 August 2017

4

1 reference

Methodological issues in the epidemiological study of the teratogenicity of drugs

3 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.4.357

Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.4.357

Maternal use of selective serotonin reuptake inhibitors and risk of congenital malformations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.4.357

Risks associated with selective serotonin reuptake inhibitors in pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.4.357

The use of selective serotonin reuptake inhibitors during pregnancy and breast-feeding: a review and clinical aspects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.4.357

NTP-CERHR Expert Panel Report on the reproductive and developmental toxicity of fluoxetine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.4.357

Neonatal signs after late in utero exposure to serotonin reuptake inhibitors: literature review and implications for clinical applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.4.357

Pregnancy outcomes following exposure to serotonin reuptake inhibitors: a meta-analysis of clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.4.357

Delivery outcome after the use of antidepressants in early pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.4.357

Effects of selective serotonin reuptake inhibitors and venlafaxine during pregnancy in term and preterm neonates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.4.357

Maternal use of selective serotonin re-uptake inhibitors in early pregnancy and infant congenital malformations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.4.357

Antidepressant use during pregnancy and the rates of spontaneous abortions: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.4.357

Outcomes of prenatal antidepressant exposure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.4.357

Neonate characteristics after maternal use of antidepressants in late pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.4.357

Maternal drug use in early pregnancy and infant cardiovascular defect

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.4.357

Paroxetine (Paxil) and congenital malformations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.4.357

Antidepressant drugs during pregnancy and infant congenital heart defect

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.4.357

Follow-up of children of depressed mothers exposed or not exposed to antidepressant drugs during pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.4.357

Perinatal outcome following third trimester exposure to paroxetine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.4.357

Selective serotonin reuptake inhibitors in pregnant women and neonatal withdrawal syndrome: a database analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.4.357

Neonatal abstinence syndrome after in utero exposure to selective serotonin reuptake inhibitors in term infants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.4.357

Neurodevelopment of children exposed in utero to antidepressant drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.4.357

Prolonged prenatal psychotropic medication exposure alters neonatal acute pain response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.4.357

Pain reactivity in 2-month-old infants after prenatal and postnatal serotonin reuptake inhibitor medication exposure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.4.357

Birth outcomes after prenatal exposure to antidepressant medication

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.4.357

Neonatal outcomes after prenatal exposure to selective serotonin reuptake inhibitor antidepressants and maternal depression using population-based linked health data

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.4.357

Pregnancy outcome following gestational exposure to venlafaxine: a multicenter prospective controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.4.357

Pregnancy outcome of women exposed to bupropion during pregnancy: a prospective comparative study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.4.357

Early first-trimester sibutramine exposure : pregnancy outcome and neonatal follow-up.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.4.357

An assessment of lithium using the IEHR Evaluative Process for Assessing Human Developmental and Reproductive Toxicity of Agents. IEHR Expert Scientific Committee

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.4.357

Maternal valproic acid and congenital neural tube defects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.4.357

Increased rate of major malformations in offspring exposed to valproate during pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.4.357

The association between prenatal stress and infant birth weight and gestational age at birth: a prospective investigation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.4.357

Do stressful life events affect duration of gestation and risk of preterm delivery?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.4.357

Implications of antenatal depression and anxiety for obstetric outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.4.357

Relapse of major depression during pregnancy in women who maintain or discontinue antidepressant treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.4.357

Pregnancy outcome following first-trimester exposure to fluoxetine (Prozac)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.4.357

Effects of first-trimester fluoxetine exposure on the newborn.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.4.357

Pregnancy outcome following maternal use of the new selective serotonin reuptake inhibitors: a prospective controlled multicenter study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.4.357

Citalopram in pregnancy and lactation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.4.357

Effects of exposure to selective serotonin reuptake inhibitors during pregnancy on serotonergic symptoms in newborns and cord blood monoamine and prolactin concentrations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.4.357

Fluoxetine use in early pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.4.357

The impact of depression and fluoxetine treatment on obstetrical outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.4.357

Maternal selective serotonin reuptake inhibitor use during pregnancy and newborn neurobehavior

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.4.357

Citalopram use in pregnancy: prospective comparative evaluation of pregnancy and fetal outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.4.357

Psychomotor development in children exposed in utero to benzodiazepines, antidepressants, neuroleptics, and anti-epileptics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.4.357

21 January 2018

Identifiers

DOI

10.1517/14740338.6.4.357

1 reference

3 August 2017

1 reference

PubMed ID

17688379